SCHEMBL5208036

SCHEMBL5208036

CCC(C)NC(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cc1F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.73
PDGFRA P16234 13/20 0.73
AXL P30530 5/20 0.73
KIT P10721 2/20 0.73
FGFR2 P21802 2/20 0.73
MET P08581 3/20 0.60
BMPR1B O00238 1/20 0.60
PLK4 O00444 1/20 0.60
AURKA O14965 1/20 0.60
GAK O14976 1/20 0.60
EPHB6 O15197 1/20 0.60
RIPK2 O43353 1/20 0.60
STK10 O94804 1/20 0.60
ABL1 P00519 1/20 0.60
EGFR P00533 1/20 0.60
LCK P06239 1/20 0.60
FYN P06241 1/20 0.60
CSF1R P07333 1/20 0.60
YES1 P07947 1/20 0.60
LYN P07948 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204657 0.89 KDR (0.76) KDRPDGFRAAXLKITFGFR2
SCHEMBL5208548 0.87 KDR (0.79) KDRPDGFRAAXLKITFGFR2
SCHEMBL5202465 0.86 KDR (0.65) KDRPDGFRAAXLKITFGFR2
SCHEMBL5208828 0.86 KDR (0.75) KDRPDGFRAAXLKITFGFR2
SCHEMBL4481241 0.86 PDGFRA (0.77) KDRPDGFRAAXLKITFGFR2
SCHEMBL4477818 0.86 PDGFRA (0.77) KDRPDGFRAAXLKITFGFR2
SCHEMBL4480165 0.86 PDGFRA (0.77) KDRPDGFRAAXLKITFGFR2
SCHEMBL5202090 0.85 KDR (0.76) KDRPDGFRAAXLKITFGFR2
SCHEMBL29918224 0.85 KDR (1.00) KDRPDGFRAAXLKITFGFR2
SCHEMBL1249562 0.85 KDR (1.00) KDRPDGFRAAXLKITFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS KDR 2466/4885PDGFRA 3108/4885AXL 1315/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 KDR 3106/4885PDGFRA 3103/4885AXL 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.